» Articles » PMID: 22270940

Prevention of Heart Failure in the Elderly: When, Where and How to Begin?

Overview
Journal Heart Fail Rev
Date 2012 Jan 25
PMID 22270940
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Significant growth in the elderly population (age ≥ 65 years) with heart failure (HF) has taken place in developed countries and is occurring in most developing countries. Projections from population studies in the United States, Europe and other developed countries suggest that this trend will very likely continue and tax healthcare systems worldwide. Prevention of HF in the elderly should be a healthcare priority. Preventive strategies are urgently needed to combat the rising burden of HF and related complications in elderly men and women of tomorrow. The strategies should address the aging continuum and the cumulative impact of lifelong exposure to cardiovascular (CV) risk factors and consider the associated pathobiology and pathophysiology of aging for optimal impact. Besides implementation of conventional primary and secondary prevention measures in young and older adults, more emphasis should be placed on education about the role of exposure to adverse CV risk factors from early childhood in the march to HF. More research is also needed to identify optimal HF therapies for different aging subgroups ranging from young adults to the elderly and very old based on understanding of pathobiology and pathophysiology.

Citing Articles

Heart failure in nursing home residents; a cross-sectional study to determine the prevalence and clinical characteristics.

Daamen M, Hamers J, Gorgels A, Brunner-La Rocca H, Tan F, van Dieijen-Visser M BMC Geriatr. 2015; 15:167.

PMID: 26675117 PMC: 4681153. DOI: 10.1186/s12877-015-0166-1.


Heart failure in elderly patients: distinctive features and unresolved issues.

Lazzarini V, Mentz R, Fiuzat M, Metra M, OConnor C Eur J Heart Fail. 2013; 15(7):717-23.

PMID: 23429975 PMC: 4176107. DOI: 10.1093/eurjhf/hft028.

References
1.
Benedict C, Weiner D, Johnstone D, Bourassa M, Ghali J, NICKLAS J . Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. The SOLVD Investigators. J Am Coll Cardiol. 1993; 22(4 Suppl A):146A-153A. DOI: 10.1016/0735-1097(93)90480-o. View

2.
Leri A, Franco S, Zacheo A, Barlucchi L, Chimenti S, Limana F . Ablation of telomerase and telomere loss leads to cardiac dilatation and heart failure associated with p53 upregulation. EMBO J. 2002; 22(1):131-9. PMC: 140062. DOI: 10.1093/emboj/cdg013. View

3.
Wilson P, DAgostino R, Levy D, Belanger A, Silbershatz H, Kannel W . Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97(18):1837-47. DOI: 10.1161/01.cir.97.18.1837. View

4.
Davies M, Woolf N, Rowles P, Pepper J . Morphology of the endothelium over atherosclerotic plaques in human coronary arteries. Br Heart J. 1988; 60(6):459-64. PMC: 1224883. DOI: 10.1136/hrt.60.6.459. View

5.
Mora S, Yanek L, Moy T, Daniele Fallin M, Becker L, Becker D . Interaction of body mass index and framingham risk score in predicting incident coronary disease in families. Circulation. 2005; 111(15):1871-6. DOI: 10.1161/01.CIR.0000161956.75255.7B. View